Odyssey Therapeutics, Inc. (ODTX)
| Market Cap | 779.32M |
| Revenue (ttm) | 2.98M -33.5% |
| Net Income | -148.65M |
| EPS | -5.16 |
| Shares Out | 47.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,269 |
| Open | 16.55 |
| Previous Close | 16.43 |
| Day's Range | 16.50 - 16.55 |
| 52-Week Range | 15.35 - 20.30 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.00 (+93.71%) |
| Earnings Date | Jun 22, 2026 |
About ODTX
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis... [Read more]
Financial Performance
In 2025, Odyssey Therapeutics's revenue was $2.98 million, a decrease of -33.45% compared to the previous year's $4.47 million. Losses were -$148.65 million, 14.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ODTX stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 93.71% from the latest price.
News
Wedbush bullish on Odyssey Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target Odyssey’s lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor ...
Wedbush bullish on Odyssey Therapeutics, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target Odyssey’s lead candidate OD-001 is an oral RIPK2 scaffolding inhibitor ...
Odyssey Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $30 price target
Odyssey Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jeff Jones initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $40 price target The company’s lead candidate, OD-001, has demonstrated clinical proof-of...
Odyssey Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Odyssey Therapeutics (ODTX) with an Overweight rating.
Odyssey Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and no price target Odyssey is pursuing novel biology for large immunology and inflammation markets, the analyst tells…
Odyssey Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Odyssey Therapeutics (ODTX) with an Overweight rating and $26 price target Odyssey is a clinical-stage biotech working on novel mechanistic approache...
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
Odyssey Therapeutics shares rose 11.1% in its Nasdaq debut on Friday, giving the biopharmaceutical firm a valuation of $899.9 million.
Biotech firm Odyssey raises $279 million in upsized US IPO
Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public offering, the company said on Thursday.
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoim...
Biotech firm Odyssey targets $810 million in valuation in US IPO
Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States.
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D.
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseas...
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics announced the appointment of Jolie M. Siegel, Executive Vice President, General Counsel.
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development
BOSTON--(BUSINESS WIRE)--Dennis Dean, Ph.D., appointed as Executive Vice President and Head of Non-Clinical Development at Odyssey Therapeutics.
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
BOSTON--(BUSINESS WIRE)--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics today announced the closing of a $213 million Series D financing.
Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO
Odyssey Therapeutics, a Phase 2-ready biotech developing precision therapies for autoimmune diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Odyssey Therapeutics IPO Registration Document (S-1)
Odyssey Therapeutics has filed to go public with an IPO on the NASDAQ.